AstraZeneca’s Atacand For Congestive Heart Failure To Receive FDA Cmte. Review
The agency’s cardio-renal committee will consider three sub-indications for Atacand in the treatment of congestive heart failure. The meeting will be held on Feb. 24.
The agency’s cardio-renal committee will consider three sub-indications for Atacand in the treatment of congestive heart failure. The meeting will be held on Feb. 24.